What is resolution of inflammation?
Resolution of inflammation is the active, programmed winding-down of an inflammatory response, driven by specialised pro-resolving mediators and host-directed enzyme control rather than by simple immune suppression.
What is resolution of inflammation?
Resolution of inflammation is the active, programmed termination of an inflammatory response — the process by which a tissue returns from an activated immune state to homeostasis. It is distinct from immunosuppression: resolution is an endogenous programme of mediator class-switching, clearance of apoptotic cells and debris, and restoration of tissue function, rather than a passive decay of inflammatory signalling. In the research literature the term is used interchangeably with inflammatory resolution and, where the lipid mediators are the subject, with pro-resolving signalling. The evidence block for this page does not supply a formal chemical identifier, sequence, formula or molecular weight for resolution as a process; it is a biological programme, not a single molecular entity, and the identifiers that appear in the cited work belong to the individual compounds and proteins studied within it.
The work summarised here centres on two overlapping arms of that programme: the specialised pro-resolving mediator (SPM) lipid class and its receptor-level signalling, and host-directed control of matrix metalloproteinase (MMP) activity relative to tissue inhibitors of metalloproteinases (TIMPs) [3][4].
Research Studies
Specialised pro-resolving mediators and inflammation-induced vascular ageing in obese hypertensive patients
A registered clinical trial is examining oral SPM supplementation in obese hypertensive patients, a population in which cardiovascular risk factors — obesity, diabetes, high blood pressure, high cholesterol and smoking — are associated with elevated risk of myocardial infarction, stroke and peripheral artery disease [2]. The trial rationale notes that even under optimal treatment, high-risk individuals retain a residual cardiovascular risk attributed primarily to vascular lesions, damage within the blood vessels that is largely driven by inflammation, an activated immune state that is more pronounced in overweight individuals [2]. The study is designed to test whether oral SPM supplementation affects inflammation-induced vascular ageing in that population [2].
Doxycycline and resolution of inflammation in pulmonary tuberculosis
In pulmonary tuberculosis, a Phase 2b double-blind randomised controlled trial reported that adjunctive doxycycline therapy was safe, accelerated resolution of inflammation, suppressed tissue-damaging enzyme activity and decreased pulmonary cavity volume [4]. The follow-on Phase III programme is designed to determine whether eight weeks of adjunctive doxycycline alongside standard pulmonary TB treatment can reduce pulmonary impairment after tuberculosis (PIAT) and improve cardiovascular outcomes [4]. The rationale links post-tuberculosis chronic ill health — including PIAT and cardiovascular disease — to processes that persist after bacterial eradication [4].
Doxycycline and MMP/TIMP imbalance in central nervous system tuberculosis
In central nervous system tuberculosis (CNS-TB), mortality under current standard of care remains 30–50% even at tertiary hospital centres, where standard management is anti-tuberculous therapy with adjunctive corticosteroids [3]. In CNS-TB the activity of pathogenic host matrix metalloproteinases is unopposed to tissue inhibitors of metalloproteinases, producing a matrix-degrading phenotype that may drive worse outcomes [3]. In a prior established CNS-TB murine model, the investigators demonstrated that adjunctive MMP inhibition using doxycycline — an animal-model finding, not a human outcome — supported progression to a clinical trial of adjunctive doxycycline for CNS-TB [3].
Follistatin and atherosclerotic lesion burden in mice
Follistatin (FST) binds to and neutralises members of the transforming growth factor-beta (TGF-β) superfamily, regulating skeletal muscle, adipose and bone homeostasis, and it promotes adipose browning and energy metabolism with improved plasma lipid profiles and metabolic health in mice [1]. Transcriptomic and metabolomic analysis of the Hybrid Mouse Diversity Panel found that Fst expression was negatively correlated with aortic lesion area, prompting investigation of FST's anti-atherogenic potential in the context of the association between brown adipose tissue activation and reduced atherosclerosis [1]. These are mouse and panel-derived findings.
Comparison of host-directed and mediator-directed approaches in the cited evidence
| Approach | Agent / mediator | Model or population | Reported finding |
|---|---|---|---|
| Host-directed enzyme control | Adjunctive doxycycline | Pulmonary TB, Phase 2b RCT; Phase III planned | Safe; accelerated resolution of inflammation; suppressed tissue-damaging enzyme activity; decreased pulmonary cavity volume [4] |
| Host-directed enzyme control | Adjunctive doxycycline | CNS-TB; prior murine model, clinical trial registered | MMP inhibition demonstrated in the murine model [3] |
| Mediator supplementation | Oral SPM | Obese hypertensive patients | Trial designed to test effect on inflammation-induced vascular ageing [2] |
| Endogenous protein signalling | Follistatin (FST) | Mice; Hybrid Mouse Diversity Panel | Fst expression negatively correlated with aortic lesion area [1] |
Reference-only supporting findings
Two further papers in the evidence block support the wider context without forming the substance of this page. A structured narrative review covering 2000–2025 synthesised evidence on the antimicrobial, immunomodulatory and regenerative properties of dental pulp stem cells in plaque-induced gingivitis and oral biofilm infections [5]. Separately, work on recombinant Klotho protein reported protection of tissues by mitigating the detrimental effects of sterile inflammation after haemorrhagic shock, a condition of systemic hypoperfusion that induces inflammatory responses, oxidative stress and apoptosis and can lead to multiple organ failure [6].
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning — https://pubmed.ncbi.nlm.nih.gov/42439678/
- [2] The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients — https://clinicaltrials.gov/study/NCT07038252
- [3] Adjunctive Doxycycline for Central Nervous System Tuberculosis — https://clinicaltrials.gov/study/NCT06446245
- [4] Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis — https://clinicaltrials.gov/study/NCT05473520
- [5] Dental Pulp Stem Cells for the Management of Plaque Biofilm-Associated Infections: A Review — https://europepmc.org/article/PMC/PMC13140043
- [6] Recombinant Klotho Protein Protects Tissues by Mitigating the Detrimental Effects of Sterile Inflammation After Hemorrhagic Shock — https://europepmc.org/article/PMC/PMC13313470